{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/51137"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/51137","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Investigating the role of NKX2-1 in human lung development","abstract":"NK2 Homeobox 1 (NKX2-1) is a critically important transcription factor in lung development, with all lung epithelia being derived from an NKX2-1+ progenitor pool. Nkx2-1-/- mice have severely hypoplastic lungs and tracheoesophageal fistula. Loss of NKX2-1 in the context of lung adenocarcinoma results in fate loss and is associated with progression to metastasis. Humans with heterozygous NKX2-1 mutations develop respiratory insufficiency, hypothyroidism, and neurological problems, a disease known broadly as brain-lung-thyroid syndrome. Despite its known importance, the role of NKX2-1 in human development is not fully defined. Here, we use an induced pluripotent stem cell (iPSC) model of early lung development, patient-derived iPSC lines with NKX2-1 mutations, and clustered short interspersed short palindromic repeats (CRISPR) gene editing to study NKX2-1’s role in development. Using this platform, we identified broad transcriptomic differences between mutant and CRISPR-corrected cells that increasingly diverged over developmental time, with mutant alveolar cells failing to properly induce alveolar type 2 (ATII) cell fate, while also upregulating non-lung endodermal markers, of which many are NKX2-1 genomic target sites. Based on the finding that we saw more transcriptomic differences in alveolar versus airway differentiations, we hypothesized that two functioning copies of NKX2-1 are needed for proper alveolar, but not airway development. We performed in vivo competition assays between Nkx2-1 heterozygous and wild-type cells via blastocyst complementation, revealing Nkx2-1 heterozygous cells are at a competitive disadvantage in alveolar, but not airway development. Next, we identified aberrant transcription factor activity consequential to aberrant NKX2-1 activity, highlighting how crosstalk between transcription factors can influence alveolar development. Of note, we identified aberrant mothers against decapentaplegic homolog 3 (SMAD3) activity in mutant cells and were able to rescue gene expression of some NKX2-1 targets via treatment with a transforming growth factor beta (TGFβ) pathway inhibitor. In conclusion, these findings significantly advance knowledge of a critically important transcription factor in human lung development. Future directions will further tease apart NKX2-1’s crosstalk with other developmentally important pathways and seek to identify the role NKX2-1 plays in chromatin remodeling.","abstract_html":"NK2 Homeobox 1 (NKX2-1) is a critically important transcription factor in lung development, with all lung epithelia being derived from an NKX2-1+ progenitor pool. Nkx2-1-/- mice have severely hypoplastic lungs and tracheoesophageal fistula. Loss of NKX2-1 in the context of lung adenocarcinoma results in fate loss and is associated with progression to metastasis. Humans with heterozygous NKX2-1 mutations develop respiratory insufficiency, hypothyroidism, and neurological problems, a disease known broadly as brain-lung-thyroid syndrome. Despite its known importance, the role of NKX2-1 in human development is not fully defined. Here, we use an induced pluripotent stem cell (iPSC) model of early lung development, patient-derived iPSC lines with NKX2-1 mutations, and clustered short interspersed short palindromic repeats (CRISPR) gene editing to study NKX2-1’s role in development. Using this platform, we identified broad transcriptomic differences between mutant and CRISPR-corrected cells that increasingly diverged over developmental time, with mutant alveolar cells failing to properly induce alveolar type 2 (ATII) cell fate, while also upregulating non-lung endodermal markers, of which many are NKX2-1 genomic target sites. Based on the finding that we saw more transcriptomic differences in alveolar versus airway differentiations, we hypothesized that two functioning copies of NKX2-1 are needed for proper alveolar, but not airway development. We performed in vivo competition assays between Nkx2-1 heterozygous and wild-type cells via blastocyst complementation, revealing Nkx2-1 heterozygous cells are at a competitive disadvantage in alveolar, but not airway development. Next, we identified aberrant transcription factor activity consequential to aberrant NKX2-1 activity, highlighting how crosstalk between transcription factors can influence alveolar development. Of note, we identified aberrant mothers against decapentaplegic homolog 3 (SMAD3) activity in mutant cells and were able to rescue gene expression of some NKX2-1 targets via treatment with a transforming growth factor beta (TGFβ) pathway inhibitor. In conclusion, these findings significantly advance knowledge of a critically important transcription factor in human lung development. Future directions will further tease apart NKX2-1’s crosstalk with other developmentally important pathways and seek to identify the role NKX2-1 plays in chromatin remodeling.","abstract_has_math":false,"creators":["Matte, Taylor Michael"],"institution":"Boston University","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Genetics & Genomics","degree_department":null,"school":null,"contributors":[],"advisors":["Hawkins, Finn"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-11-18T19:49:40Z","subjects":["Developmental biology","Genetics","Bioinformatics"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0002-7796-7485"],"render_values":[{"text":"0000-0002-7796-7485","href":"https://orcid.org/0000-0002-7796-7485","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/51137","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/51137","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F51137","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Hawkins, Finn"]},{"key":"dc:creator","label":"Author","values":["Matte, Taylor Michael"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0002-7796-7485"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-09-04T12:23:26Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-09-04T12:23:26Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2025-09-04T01:02:18Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Genetics & Genomics"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Developmental biology","Genetics","Bioinformatics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/51137"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2024"]},{"key":"dc:description.abstract","label":"Abstract","values":["NK2 Homeobox 1 (NKX2-1) is a critically important transcription factor in lung development, with all lung epithelia being derived from an NKX2-1+ progenitor pool. Nkx2-1-/- mice have severely hypoplastic lungs and tracheoesophageal fistula. Loss of NKX2-1 in the context of lung adenocarcinoma results in fate loss and is associated with progression to metastasis. Humans with heterozygous NKX2-1 mutations develop respiratory insufficiency, hypothyroidism, and neurological problems, a disease known broadly as brain-lung-thyroid syndrome. Despite its known importance, the role of NKX2-1 in human development is not fully defined. Here, we use an induced pluripotent stem cell (iPSC) model of early lung development, patient-derived iPSC lines with NKX2-1 mutations, and clustered short interspersed short palindromic repeats (CRISPR) gene editing to study NKX2-1’s role in development. Using this platform, we identified broad transcriptomic differences between mutant and CRISPR-corrected cells that increasingly diverged over developmental time, with mutant alveolar cells failing to properly induce alveolar type 2 (ATII) cell fate, while also upregulating non-lung endodermal markers, of which many are NKX2-1 genomic target sites. Based on the finding that we saw more transcriptomic differences in alveolar versus airway differentiations, we hypothesized that two functioning copies of NKX2-1 are needed for proper alveolar, but not airway development. We performed in vivo competition assays between Nkx2-1 heterozygous and wild-type cells via blastocyst complementation, revealing Nkx2-1 heterozygous cells are at a competitive disadvantage in alveolar, but not airway development. Next, we identified aberrant transcription factor activity consequential to aberrant NKX2-1 activity, highlighting how crosstalk between transcription factors can influence alveolar development. Of note, we identified aberrant mothers against decapentaplegic homolog 3 (SMAD3) activity in mutant cells and were able to rescue gene expression of some NKX2-1 targets via treatment with a transforming growth factor beta (TGFβ) pathway inhibitor. In conclusion, these findings significantly advance knowledge of a critically important transcription factor in human lung development. Future directions will further tease apart NKX2-1’s crosstalk with other developmentally important pathways and seek to identify the role NKX2-1 plays in chromatin remodeling."]},{"key":"dc:title","label":"Title","values":["Investigating the role of NKX2-1 in human lung development"]}]}],"canonical_facts":{"dc:contributor.advisor":["Hawkins, Finn"],"dc:creator":["Matte, Taylor Michael"],"dc:date.accessioned":["2025-09-04T12:23:26Z"],"dc:date.available":["2025-09-04T12:23:26Z"],"dc:date.issued":["2024"],"dc:date.updated":["2025-09-04T01:02:18Z"],"dc:description":["2024"],"dc:description.abstract":["NK2 Homeobox 1 (NKX2-1) is a critically important transcription factor in lung development, with all lung epithelia being derived from an NKX2-1+ progenitor pool. Nkx2-1-/- mice have severely hypoplastic lungs and tracheoesophageal fistula. Loss of NKX2-1 in the context of lung adenocarcinoma results in fate loss and is associated with progression to metastasis. Humans with heterozygous NKX2-1 mutations develop respiratory insufficiency, hypothyroidism, and neurological problems, a disease known broadly as brain-lung-thyroid syndrome. Despite its known importance, the role of NKX2-1 in human development is not fully defined. Here, we use an induced pluripotent stem cell (iPSC) model of early lung development, patient-derived iPSC lines with NKX2-1 mutations, and clustered short interspersed short palindromic repeats (CRISPR) gene editing to study NKX2-1’s role in development. Using this platform, we identified broad transcriptomic differences between mutant and CRISPR-corrected cells that increasingly diverged over developmental time, with mutant alveolar cells failing to properly induce alveolar type 2 (ATII) cell fate, while also upregulating non-lung endodermal markers, of which many are NKX2-1 genomic target sites. Based on the finding that we saw more transcriptomic differences in alveolar versus airway differentiations, we hypothesized that two functioning copies of NKX2-1 are needed for proper alveolar, but not airway development. We performed in vivo competition assays between Nkx2-1 heterozygous and wild-type cells via blastocyst complementation, revealing Nkx2-1 heterozygous cells are at a competitive disadvantage in alveolar, but not airway development. Next, we identified aberrant transcription factor activity consequential to aberrant NKX2-1 activity, highlighting how crosstalk between transcription factors can influence alveolar development. Of note, we identified aberrant mothers against decapentaplegic homolog 3 (SMAD3) activity in mutant cells and were able to rescue gene expression of some NKX2-1 targets via treatment with a transforming growth factor beta (TGFβ) pathway inhibitor. In conclusion, these findings significantly advance knowledge of a critically important transcription factor in human lung development. Future directions will further tease apart NKX2-1’s crosstalk with other developmentally important pathways and seek to identify the role NKX2-1 plays in chromatin remodeling."],"dc:identifier.orcid":["0000-0002-7796-7485"],"dc:identifier.uri":["https://hdl.handle.net/2144/51137"],"dc:language.iso":["en_US"],"dc:subject":["Developmental biology","Genetics","Bioinformatics"],"dc:title":["Investigating the role of NKX2-1 in human lung development"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Genetics & Genomics"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T19:49:40Z"}